The Swedish pharma company Orexo and biotech firm Abera Bioscience announced today that they have joined forces to develop mucosal vaccines, including an influenza vaccine candidate. The collaboration ...

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better for treating some subgroups than others. Prasinezumab was originally ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US. Ryoncil (remestemcel-L-rknd) has been granted approval by the FDA for ...

Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity drugs Mounjaro and Zepbound.

Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases.

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program. PTC Therapeutics announced this week that it has made a deal with ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to identify and validate new drug targets for neurodegenerative diseases. GSK and ...

The sickle cell gene therapies developed by Bluebird Bio and Vertex will be the first to be offered under the new scheme. A major issue with gene and cell therapies is the upfront cost. While these ...

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo delivery expertise to develop new genetic medicines. The launch of nChroma is ...

The company will start enrolling patients with Stargardt disease in the first half of 2025. The Spanish genetic medicines company SpliceBio announced today that the FDA has cleared its investigational ...

The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma’s marketing authorization application for AVT05, a biosimilar to Johnson & Johnson’s biologic Simponi (golimumab), which is ...